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Abstract Aims/hypothesis. Phosphoinositide 3-kinase (PI 3K) plays a central part in the mediation of insulin-stimulated glucose disposal. No genetic studies of this enzyme in human syndromes of severe insulin resistance have been previously reported. Methods. Phosphoinositide 3-kinase p85a regulatory subunit cDNA was examined in 20 subjects with syndromes of severe insulin resistance by single strand conformational polymorphism and restriction fragment length polymorphism analyses. Insulin-stimulated phosphoinositide 3-kinase activity and recruitment into phosphotyrosine complexes of variants of p85a were studied in transiently transfected HEK293 cells. Phosphopeptide binding characteristics of wild-type and mutant p85a-GST fusion proteins were examined by surface plasmon resonance. Results. The common p85a variant, Met 326 I1e, was identified in 9 of the 20 subjects. Functional studies of the Met 326 Ile variant showed it to have equivalent insulin-stimulated lipid kinase activity and phosphotyrosine recruitment as wild-type p85a. A novel heterozygous mutation, Arg 409 Gln, was detected in one subject. Within the proband's family, carriers of the mutation had a higher median fasting plasma insulin (218 pmol/l) compared with wild-type relatives (72 mol/l) (n = 8 subjects, p = 0.06). The Arg 409 Gln p85a subunit was associated with lower insulin-stimulated phosphoinositide 3-kinase activity compared with wild-type (mean reduction 15 %, p < 0.05, n = 5). The recruitment of Arg 409 Gln p85a into phosphotyrosine complexes was not significantly impaired. GST fusion proteins of wild-type and mutant p85a showed identical binding to phosphopeptides in surface plasmon resonance studies. Conclusion/interpretation. Mutations in p85a are uncommon in subjects with syndromes of severe insulin resistance. The Met 326 Ile p85a variant appears to have no functional effect on the insulin-stimulated phosphoinositide 3-kinase activity. The impaired phosphoinositide 3-kinase activity of the Arg ways has opened up a large number of candidate genes potentially responsible for cases of genetically determined insulin resistance [7] .
Insulin activates the intrinsic tyrosine kinase of its receptor which phosphorylates YXXM amino acid sequence motifs in a number of proteins, primarily the insulin receptor substrates (IRS) [8, 9] which then recruit a variety of proteins through their SH2 domains. The class I a phosphoinositide 3-kinases (PI 3K) are recruited in this way [10] . Insulin-stimulated activation of PI 3K results in the generation of phosphorylated lipid products from membrane-bound substrates which act as intracellular second messengers [11] . Activation of PI 3K precedes a number of important signalling events including stimulation of phosphatidylinositol [3, 4, 5 ] P 3 -dependent kinase-1 (PDK-1) dependent kinase-1 (PDK-1), protein kinase B, p70 s6 kinase, GLUT4 vesicle translocation to the plasma membrane and inhibition of glycogen synthase kinase-3. Moreover, PI 3K is necessary, if not sufficient, for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues [12, 13] .
The involvement of PI 3K in mediating downstream metabolic effects of insulin led us to postulate that defects in insulin-stimulated PI 3K activity might explain severe insulin resistance in some people. To date, no systematic study of the PI 3K genes in the syndromes of severe insulin resistance has been undertaken. Impaired PI 3K activation in cultured dermal fibroblasts in a small number of subjects with the pseudoacromegalic phenotype of severe insulin resistance has, however, recently been described [14±16] indicating the possibility that primary defects in PI 3K genes could be found.
The class I a 3K activated by insulin consist of a 110 000 M r catalytic subunit (p110) tightly linked to an 85 000 M r regulatory subunit (p85) [11] . A number of forms of the regulatory subunit exist, but all of these contain two SH2 domains, which mediate the recruitment of the PI 3K heterodimer to signalling complexes containing tyrosine phosphorylated YXXM motifs. Two highly homologous full-length class I a PI 3K regulatory subunit genes have been identified, these being p85a and p85b [17±21] . Both p85a and p85b contain two C-terminal region SH2 domains which are separated by the catalytic subunit binding domain (Fig. 1) . Also common to both isoforms and situated in the N-terminal region are an SH3 domain, a BCR (Breakpoint-Cluster Region) homology domain and two short proline-rich domains (Fig. 1) . A third regulatory subunit gene termed p55g has recently been identified which encodes a shorter gene product lacking these N-terminal domains [22] . Additionally, two major splice variants of the p85a gene have been described which result in truncated proteins also lacking the N-terminal domains [23±26]. We have previously established that p85a and its splice variants are all expressed and regulated by insulin in human muscle which is a major site of insulin-mediated glucose disposal [27] . The importance of these splice variants has been shown recently in a p85a gene knockout mouse in which the fulllength p85a gene product is deleted, but the splice variants are still expressed [28] . These p85a knockout mice show major changes in their profile of glucose metabolism indicating that p85a and its splice variants play a crucial part in insulin-mediated glucose disposal in vivo. Although sequence variants of p85 a have been described in studies of human cohorts, no functional studies of natural variants have been reported. We describe here the results of a search for genetic variation in the p85a regulatory subunit in subjects with severe insulin resistance and the biochemical analysis of two amino acid variants of this protein.
Materials and methods
Clinical subjects. Subjects had all been referred to Addenbrooke's hospital with a diagnosis of severe insulin resistance (Table 1 ) which was confirmed, where possible, by pronounced hyperinsulinaemia during a standard 75-g oral glucose tolerance test. Measurements of specific insulin were made by a chemiluminescent immunoassay (Access Immunoassay System, Beckman Instruments, High Wycombe, UK.
Total RNA extraction and cDNA synthesis. Dermal fibroblasts derived from subject skin biopsies were grown to confluence in DMEM (Sigma, Poole, UK) containing 10 % fetal bovine serum, 25 mol/l glucose, 2 mol/l glutamine, 100 units penicillin ml/and 100 mg streptomycin ml/l and lysed directly in TRIzol reagent (GibcoBRL, Paisley, UK). Lymphocytes derived from subject wholeblood samples were transformed using EpsteinBarr virus to create independent cell lines (EBVLs). These were grown in RPMI-1640 medium (Sigma) containing additions as above until visibly clumping. Cells in suspension were then pelleted by centrifugation at 2000 g for 5 min and resuspended in TRIzol reagent. Total RNA from subject relatives was extracted from buffy coat preparations of venous blood samples. Total RNA was reverse transcribed into cDNA using random hexamer oligonucleotides as primers (Promega, Southampton, UK).
Polymerase chain reaction. We amplified 200 ng cDNA by the polymerase chain reaction (PCR) method using 1 unit of Taq DNA polymerase (Bioline, London, UK), 0.3 mmol/l primers Single-strand conformational polymorphism (SSCP) and heteroduplex analysis. We amplified p85a cDNA by PCR in 12 overlapping segments of approximately 250 bp by using primer pairs specific to the human p85a cDNA sequence (Table 2) . Radiolabelled PCR products were generated by including 0.04±0.07 MBq a 32 P dCTP (Amersham Pharmacia Biotech, Little Chalfont, UK) in the PCR mixture. These were diluted in formamide loading buffer to a uniform concentration and run on non-denaturing gels under two conditions: firstly, mutation detection enhancement (MDE) gel (Flowgen, Ashby-dela-Zouch, UK) run at room temperature at 8 W for 6 h and secondly, 6 % polyacrylamide gel run at 80°C at 40 W for 4 h. Gels were dried, exposed to autoradiography film (Biomax MR, Kodak, Anachem, Luton, UK) for 24±48 h and then developed.
DNA sequencing. Polymerase chain reaction products of interest were generated using one biotinylated primer and the PCR product isolated using streptavidin-coated magnetic beads (Dynabeads, Dynal, UK). Single-strand DNA was then sequenced directly using Ile variant was introduced into pGEX2T.p85a by PCR of a Pst I/Sal I fragment and then sub-cloned into pcDNA3.-p85aMyc. The plasmid pcDNA3.p85aMycR409Q was generated by sub-cloning a BamH I/Xba I fragment from pBS.p85a-MycR409Q into the pcDNA3 backbone (Invitrogen, Leek, The Netherlands). The human p110a coding sequence (a gift from M. D. Waterfield) was inserted into pcDNA3 and a C-terminal FLAG epitope tag was added using PCR (pcDNA3.-p110a.FLAG).
Transient transfection. We grew HEK293 cells to 60 % confluence in 60 cm 2 dishes and transfected with calcium phosphate using 8 mg pcDNA3.p85aMyc and 6 mg pcDNA3.p110aFLAG or empty vector. Transfection efficiencies by this technique were estimated by transfection with pTracer (Invitrogen) a vector which results in overexpression of green fluorescent protein. Cell counting using a fluorescence microscope (Carl Zeiss microscope, Welwyn Garden City, UK) showed that transfection efficiencies ranged from 20±25 %. Cells were harvested 36 h after transfection. All cells were serum-starved for 16 h and then stimulated with 100 nmol/l insulin for 10 min. Cells were lysed in 1 ml PI 3K lysis buffer (137 mmol/l NaCl, 2.7 mmol/l KCl MgCl 2 , 0.5 mmol/l Na 3 VO 4 , 1 % v/v Nonidet P40, 10 % w/v glycerol, 20 mmol/l TRIS pH 8.0 at 4°C, 21 mmol/l leupeptin, 0.2 mmol phenylmethylsulphonylfluoride). Insoluble material was removed by centrifugation at 10000 g for 5 min.
Immunoprecipitation and immunoblotting. Cleared cell lysate (160 ml) was incubated at 4°C for 90 min on a rotating wheel with 1.5 ml of mouse monoclonal antiphosphotyrosine antibody (PY99, Santa Cruz Biotechnology, Autogen-Bioclear, Calne, UK). Then 2.5 mg of rehydrated Protein A-agarose beads (Sigma) were added, incubated for a further 60 min and washed three times. Protein samples were boiled for 5 min in Laemmli sample buffer, resolved by SDS-PAGE and transferred to Immobilon-P polyvinylidene fluoride membranes (Millipore, Bedford, Ma., USA) by semi-dry blotting. The membranes were blocked in 1 % bovine serum albumin (BSA) in phosphate-buffered saline (PBS)-Tween 0.1 % v/v (Sigma) incubated with primary antibody, washed with PBSTween, incubated with secondary antibody and finally washed in PBS-Tween. The Myc epitope was detected with 9E10 primary antibody (a gift from G. Evan) and I
125
-labelled secondary antibody, the membranes were exposed to a phosphorimager screen overnight and quantified using a Fujix BAS 2000 phosphorimager (Raytek Scientific, Sheffield, UK). The FLAG epitope was detected with polyclonal primary antibody (Santa Cruz Biotechnology) and horseradish peroxidaselinked secondary antibody and enhanced chemiluminescence reagent (Amersham Pharmacia Biotech), then membranes were exposed to autoradiography film and bands were quantified.
Phosphoinositide 3-kinase assays. The technique for the measurement of PI 3K activity was adapted from a previously published technique [29] . Immunoprecipitates from 160 ml cleared cell lysate were collected and washed three times in PI 3K lysis buffer, two times in buffer 2 (0.5 mol/l LiCl, 0.1 mol/l TRISHCl pH 8.0 at 4°C), once in buffer 3 (0.15 mol/l NaCl, 1 mol/l EDTA, 10 mol/l TRIS-HCl pH 7.6 at 4°C) and once in buffer 4 (20 mol/l HEPES, 1 mol/l dithiothreitol, 5 mol/l MgCl 2 pH 7.6 at 4°C). The immunoprecipitates were then resuspended in 40 ml kinase assay buffer (20 mol/l b-glycerophosphate pH P-ATP in 40 ml reaction mix (3 mol/l cold ATP, 7.6 mol/l MgCl 2 in kinase assay buffer) were then added and incubated for a further 15 min before terminating the lipid kinase reaction with 0.45 ml CHCl 3 /MeOH 1:2 v/v. The phospholipids were extracted by two washes in CHCl 3 /0.1 mol/l HCl 1:1 v/v, dried in a vacuum centrifuge at 1000 g for 30 min and the residue dissolved in 35 ml CHCl 3 / MeOH/0.1 mol/l HCl 200:100:1 v/v and separated by thin layer chromatography (TLC) as described elsewhere [30] . The dried TLC plates were exposed on a phosphorimager screen for 30 min and the amount of phosphatidylinositol 3-phosphate produced was quantified using a Fujix BAS 2000 phosphorimager.
Glutathione-S-transferase-fusion protein expression. Glutathione-S-transferase (GST)-fusion proteins were induced by isopropyl-b-d-thiogalactoside (IPTG) in E. coli and purified from bacterial lysates by glutathione sepharaose columns (Amersham Pharmacia Biotech).
Phosphopeptide binding studies. A biotinylated-tyrosine-phosphorylated 17mer peptide corresponding to the PDGF b receptor Y751 SH2 domain binding site (DMSKDESV-D*YVPMLDMK) was immobilised on an avidin-coated surface plasmon resonance biosensor chip (BIAcore, Uppsala, Sweden). Binding of the p85a GST fusion proteins to this biosensor surface was completed by the addition of either monophosphorylated non-biotinylated 17mer peptide or a diphosphorylated non-biotinylated 19mer peptide (GG*YMDMSKDESSVD*YVPML) containing 2 YXXM motifs corresponding to the Y740 and Y751 SH2 domain binding sites of the PDGF b receptor [31] .
Results
Molecular scanning. The p85a coding sequence was examined in 20 subjects (17 female, 3 male) with features of severe insulin resistance using revers-transcription-PCR-single-strand conformational polymorphism (RT-PCR-SSCP) and heteroduplex analysis. All SSCP and heteroduplex variants were further studied by direct nucleotide sequencing. Three variants were detected in this cohort which on DNA sequencing showed two silent polymorphisms (TAC®TAT at nucleotide 261 in seven subjects, ATT®ATC at nucleotide 663 in two subjects) and a single-point mutation (CGG®CAG at codon 409) which resulted in a novel heterozygous missense amino acid change Arg 409 Gln in one person (Fig. 1) . Analysis of the p55a splice variant of p85a, which contains a unique 32 amino acid N-terminal extension, showed no additional SSCP variants. In agreement with others we also found that all cDNA samples sequenced at amino acid residue 330 coded for Asp suggesting that there is an error in the published sequence of p85a [32] . Also of note was the absence of mutations in the p85a gene in the pseudoacromegalic patients whom we have previously reported to have impaired insulin-stimulated PI 3K activity in their cultured dermal fibroblasts [15] .
The subject carrying the Arg 409 Gln missense variant was a 23-year-old Caucasian female with features of the Type A syndrome who began to develop hirsutism, oligomenorrhoea and impaired glucose tolerance in her late teenage years (subject 14 in Table 1 ). She had a history of acanthosis nigricans since infancy. Biochemical evaluation during 2-h 75-g OGTT showed increased plasma specific insulin both fasting 259 pmol/l (95 % reference range < 80 pmol/l) and at 2 h 3505 pmol/l with corresponding plasma glucoses 4.5 and 10.3 mmol/l. This subject had previously been studied for the presence of insulin receptor gene mutations and none were found.
Family and population genetic studies. Because the Arg 409
Gln variant causes the loss of an Msp I restriction site, available members of the proband's family were genotyped by restriction fragment length polymorphism (RFLP) analysis and evaluated biochemically by fasting plasma insulin and glucose measurements. Genotype results obtained from RT-PCR of ACCAGCCAATTTCTTCAGGC  205  2  GCTCTTGGATTCAGTGATGG  TTGATAAGAAGAGGCGGGGC  286  3  GATCTTGCAGAGCAGTTTGC  GGTAAGTCCAGGAGATAGCG  232  4  GTGCACGTTTTGGCTGACGC  TGCTGGAGGTTTGAGAGAGC  231  5  TCATCAGTATTGGCTTACGC  GTTATTCATACCGTTGTTGGC  273  6  CCTCCTAAACCACCAAAACC  GGTTAATGGGTCAGAGAAGC  269  7  CTCTTACACTAAGGAAAGGGG  TGACAACTTGATCCTGTTGG  206  8  CTCTAGCTCAGTATAATCCC  AAATGCTTCAATAGCTGTCC  226  9  GAAGAATATACCCGCACATCC  ATTTCTCGATACTCAGCTGC  284  10  GACAGTAGAAGAAGATTGGAAG  TGCTTCCAACATTCCATGTC  267  11  GAAGACCAATATTCACTGGTGG  CACCAGTTCTTTCAGAGAGC  275  12  AACTGGCTATGGCTTTGCCG  GATGGCTTCGTTTCTGCAGC  259  p55a  ATGTACAATACTGTTTGGAATATGG  GTTATTCATACCGTTGTTGGC  171 total RNA extracted from buffy coat preparations were confirmed by an independent PCR using genomic DNA and a different set of primers. The heterozygous Arg
409
Gln variant was inherited through the maternal line (Fig. 2) . The proband's brother, who was also heterozygous for the Arg 409 Gln variant, was known to have had acanthosis nigricans since childhood. Individual fasting plasma insulin concentrations in all four carriers were above the normal range with a median plasma insulin in Arg 409 Gln heterozygotes of 218 pmol/l ± 69 (n = 4, medians ± SEM) compared with 72 pmol/l ± 29 (n = 4) in relatives who were wild-type at that site (p = 0.06, MannWhitney: two-tailed). All the relatives studied had normal fasting plasma glucose values (range 4.5±5.6 mmol/l).
The RFLP analysis of 271 Danish subjects (136 with Type II (non-insulin-dependant) diabetes mellitus, 135 non-diabetic) found no subjects carrying the Arg 409 Gln variant. Similarly this variant was not found in 50 non-diabetic middle-aged UK Caucasians with fasting hyperinsulinaemia (range 91±316 pmol/l) from the Isle of Ely study [33] thus confirming that this is not a common variant.
Our SSCP study did not detect the common p85a polymorphism Met 326 Ile previously reported in a Danish cohort. A specific RFLP assay for this variant [34] showed that the Met 
Functional studies
Effects of p85a variants on insulin-stimulated PI 3K enzymatic activity. To examine the effects of the variant p85a. sequences on insulin-stimulated PI 3K activity HEK293 cells were transfected with wild-type or valiant Myc-tagged p85a constructs and FLAGtagged wild-type p110a. Cells were stimulated with 100 nmol/l insulin for 10 min and the PI 3K enzymatic activity present in antiphosphotyrosine immunoprecipitates was measured. Insulin-stimulated PI 3K activity in antiphosphotyrosine immunoprecipitates from mock transfected cells were approximately 20 % of that in cells transfected with wild-type p85a and p110a (data not shown) Phosphoinositide 3-kinase activity was consistently and significantly lower in Arg 409 Gln than in wild-type transfections (76 4 % vs 100 5 %, p < 0.01, n = 5 experiments) (Fig. 3) . In contrast, cells transfected with the Met 326 I1e adaptor subunit were indistinguishable from wild type (95 11 % vs 100 5 %) (Fig. 3) . The presence of a Myc tag on the p85a constructs allowed variability in the expression of the p85a variants to be taken into account. A significant difference in PI 3K activation remained after correcting the PI 3K activities for the amount of Myc tag detected in the antiphosphotyrosine immunoprecipitates by western blotting (WT 100 % 5 vs Arg 409 Gln 85 % 4, n = 5, p < 0.05) (Fig. 3) . Correction for p85a expression in the immunoprecipitates did not alter the results with the Met 326 I1 e variant which remained similar to wild type (Fig. 3) .
The major role of p85a is to facilitate recruitment of p110a into signalling complexes so we also analysed the amount of p110a-FLAG present in the antiphosphotyrosine immunoprecipitates. This showed a similar pattern to that observed for p85a with the PI 3K activity corrected for FLAG tag being significantly lower for Arg Ile 114 % ± 10, p = NS; (Fig. 3) .
Effects of p85a variants on intrinsic activity of PI 3K complexes. To examine whether the variants affected the intrinsic PI 3K activity associated with the regulatory subunits HEK293 cells were cotransfected with wild-type and variant Myc-tagged p85a constructs and FLAG-tagged p110a. We did PI 3K assays on Myc immunoprecipitates from serum-starved cells and intrinsic activity of the expressed forms of PI 3K was calculated by correcting the PI 3K activity for the amount of Myc in the immunoprecipitates, as assessed by western blotting. These studies showed that the intrinsic activity of the Met 326
Ile and Arg

409
Gln adaptor subunits were both equivalent to wild-type p85a (WT 100 % ± 12, Met 326 Ile 101 % ± 8.3, Arg 409 Gln 98 % ± 7; n = 3, p = NS) (Fig. 4) .
Effects of p85a variants on recruitment to tyrosine phosphorylated signalling intermediates. Because amino acid residue 409 lies within the N-terminal SH2 domain of p85a, variants at this position have the potential to affect binding to phosphotyrosine residues on signalling intermediates. Recruitment of transfected PI 3K subunits into antiphosphotyrosine complexes was assessed by western blotting for Myctagged p85a and FLAG-tagged p110a in antiphosphotyrosine immunoprecipitates. Insulin-stimulated recruitment of both regulatory and catalytic subunits into phosphotyrosine complexes (Fig. 5) Gln 83 % ± 7.1; n = 5, p = NS) (Fig. 5) . Likewise, recruitment of the FLAG-tagged p110a catalytic subunit of PI 3K into phosphotyrosine complexes was similar for each of the p85a variants (WT 100 % ± 2.5, Met 326 Ile 98 % ± 7, Arg
Gln 97 % ± 4, n = 3, p = NS) (Fig. 5) . To rule out the possibility that the reduced PI 3K activity was due to the Arg 409 Gln mutant associating less tightly with the catalytic subunit we calculated the ratio of FLAG tag:Myc tag in each of the anti-phosphotyrosine immunoprecipitates and found the ratio was not significantly different between the three regulatory subunit variants (data not shown) suggesting that the adaptor variants did not have altered binding to the p110a catalytic subunit of PI 3K.
In vitro binding of Arg409Gln p85a to tyrosine phophorylated proteins. To more closely analyse the binding characteristics of the p85a variant the binding of wild-type and Arg
Gln p85a-GST fusion proteins was compared using a surface plasmon resonance biosensor device. The sensor surface was coated with a tyrosine phosphorylated 17mer peptide (DMSKDESVD*YVPMLDMK) corresponding to the Y751 site of the PDGF b receptor. Binding of the p85a-GST fusion proteins to this sensor surface was completed by the addition of either monophosphorylated l7mer peptide or a diphosphorylated 19mer peptide (GG*YMDMSKDESSVD*YVPML) corresponding to both the Y740 and Y751 of the PDGF b receptor. The half-maximum inhibitory concentrations (IC 50 ) derived from the binding curves 
Discussion
A substantial body of biochemical data attests to the importance of PI 3K in the mediation of the effects of insulin on cellular glucose metabolism [12, 13] . Evidence directly implicating dysfunction of this enzyme in human disorders of insulin action has been less readily provable. A reduction in insulin-stimulated PI 3K activity in muscle and adipose tissue from insulin-resistant subjects with Type II diabetes or obesity has been reported in a number of studies [35±37] . Impaired insulin-stimulated PI 3K activity in cultured dermal fibroblasts has been reported from subjects with the pseudoacromegalic form of severe insulin resistance suggesting the presence of an intrinsic cellular defect in the PI 3K pathway in that rare subtype of severe insulin resistance [15, 16] .
Until recently there has been little genetic evidence available to confirm the action of this enzyme in the control of whole-body insulin sensitivity in mammals. It was recently reported that mice rendered null for p85a are, surprisingly, more insulin sensitive than wild-type littermates and have a tendency to develop hypoglycaemia [28] . The experimental strategy employed did not, however, delete the alternatively spliced product of the p85a gene, p55a, which was noticeably up-regulated in metabolically active tissues from the knockout mice. As p55a appears to be capable of coupling to p110 with similar, if not greater, efficiency than p85a, this could explain the enhanced insulin sensitivity seen in these mice.
Several studies examining the p85a gene for mutations in people with Type II diabetes have been re- Ile and two common silent polymorphisms [38] , which have been previously described, were also found in our patient cohort. Association studies examining the consequences of the Met
326
Ile polymorphism have resulted in variable findings; one study has reported that in the homozygous form it is associated with a reduced insulin sensitivity index, glucose disappearance constant and glucose effectiveness [38] whereas another report showed no association with insulin sensitivity [32] . Two reports suggest that the Met 326 Ile variant is not associated with Type II diabetes [34, 38] , whereas another has reported that in female Pima Indians it is associated with a lower prevalence of Type II diabetes and a higher early phase insulin response [32] . In our group of people with severe insulin resistance we found a similar allelic frequency for the Met
Ile allele to that reported for Pima Indians (25 %) [32] . The small sample size, however, and mixed racial origin of our group precludes any definite conclusions being drawn from this observation. None of the previous studies have investigated the functional activity of the Met 326 Ile variant. In detailed functional studies we were not able to discern any functional difference between the Met 326 Ile variant and wild type in insulin-stimulated PI 3K activity, association with p110a, intrinsic activity of p85a-p110a complexes or recruitment to tyrosine phosphorylated proteins. Given the variable results of the population association studies and the consistency of our biochemical observations we conclude that this common variant is unlikely to have any major functional relevance.
In one person with severe insulin resistance, we identified the novel heterozygous missense mutation Arg 409 Gln. We have established by the study of two separate European populations that this is a rare variant. The possibility that the Arg 409 Gln mutation could have functional relevance is suggested by its location in the N-terminal SH2 domain. Recent studies have shown that the N-terminal SH2 domain has the highest affinity for tyrosine phosphorylated peptides, especially in the context of the truncated p85a splice variants [31, 39] . The potential functional importance of arginine 409 is suggested by the finding that this residue is conserved between the four published mammalian species (human, bovine, murine, rat); additionally it is conserved between the different adaptor subunits p85a and p85b, whereas in p55g it is replaced by histidine, a conservative change. Residue 409 is not directly in the phosphotyrosine-binding pocket of p85a [40] so any effect on binding to phosphotyrosine would be by effect on overall conformation. Structural modelling has suggested that the position of the non-conservative variant Arg 409 Gln within the N-terminal SH2 domain might affect the folding of p85a domains (M. Zvelebil, personal communication).
The proband of our family is a severely insulin-resistant young woman with acanthosis nigricans and hyperandrogenism. Her younger brother is also severely hyperinsulinaemic with acanthosis nigricans developing at a young age. The mutation is present in both subjects. Although the size of the available extended family is too small to provide formal genetic proof of linkage, of particular note is the proband's maternal grandmother whom despite a low body mass index has a greatly increased plasma insulin of 177 pmol/l. The multiple genetic and environmental influences on insulin sensitivity are reflected by the fact that even in families with pathogenic insulin receptor mutations there is enormous interindividual variability in severity of hyperinsulinaemia [2] . Accordingly, it is perhaps not surprising that full penetrance of the complete syndrome of severe insulin resistance is not seen in this pedigree.
In transfection studies the Arg 409 Gln mutation was consistently associated with a reduction in insulinstimulated PI 3K activity in anti-phosphotyrosine immunoprecipitates. Further experiments were undertaken to examine possible molecular mechanisms underlying this defect in signal transduction. Recruitment of the mutant p85a into phosphotyrosine-containing signalling complexes such as the insulin receptor substrates was examined. The expression of epitope-tagged forms of wild-type p85a and the Arg 409 Gln mutant confirm that within intact cells the mutation has no effect on the level of recruitment of the adapter subunit into insulin-induced signalling complexes. In addition, in vitro binding data using the BIAcore surface plasmon resonance system also showed that the Arg 409 Gln mutation had no effect on the binding of p85a to tyrosine phosphorylated peptides. The use of both monophosphorylated and diphosphorylated peptides in this study excludes the possibility of impaired binding at one or both SH2 domains due to an effect on the conformation of p85a. It could be argued that the use of phosphopeptides derived from the PDGF b receptor rather than from IRS-1 makes this observation less relevant to insulin signalling; it is known, however, that the main determinants of phosphopeptide binding to SH2 domains in this system are the presence of YXXM motifs which are present in both IRS-1 and PDGF b receptors [31] .
This leaves two further ways in which the mutant could be affecting insulin's stimulation of PI 3K activity. The simplest of these is that the catalytic activity of the p85/p110 might be lower when the mutant forms of p85a are present in the heterodimer. This is clearly not the case, however, as the epitope tagging has allowed us to directly compare the intrinsic PI 3K activity between wild-type and mutant p85a while controlling for the expression of p85a and p110a present in the immunoprecipitates and these are very similar.
The third possibility relates to the reports that full activation of PI 3K catalytic activity requires the binding of phosphotyrosyl residues to both SH2 domains of p85a [41±43] . The molecular basis of this increase in the activity of the catalytic subunit is not known, but could involve a conformational change in the SH2 domains being transferred by the inter-SH2 domain to the p110 catalytic subunit. It is therefore possible that mutations in p85a could affect insulin's ability to activate PI 3K through the phosphotyrosine interactions with the SH2 domains. Indeed, this appears to be the most likely mechanism for the adverse effect of the Arg 409 Gln mutation as its associated enzymatic activity is reduced in the face of similar recruitment to phosphotyrosine-containing signalling intermediates even though the stoichiometry of its physical interaction with p110a seems unimpaired.
How might such an apparently subtle mutation in PI 3K contribute to such a pronounced clinical phenotype? It seems implausible that heterozygosity for a mutant protein that shows only a modest decrease in its in vitro function could result in severe insulin resistance. We have recently discussed how subtle inherited defects in insulin action could lead to a progressive perturbation of glucose homeostasis through the adverse effects on insulin sensitivity of compensatory hyperinsulinaemia [44] . This phenomenon is clearly shown by the progressive development of insulin resistance and diabetes in mice rendered heterozygous null for the insulin-sensitive glucose transporter GLUT4 [45] . Alternatively, the p85a variant might only result in severe insulin resistance if it is co-inherited with other genetic factors predisposing to insulin resistance. Thus, although heterozygous knock out mice for either the insulin receptor or IRS-1 locus are largely normal, doubly heterozygous mice develop progressive severe insulin resistance and diabetes [46] . Finally, it is probable that we have underestimated the functional defect in PI 3K activation in our cellular system as endogenous PI 3K is contributing to the overall measured enzymatic activity. Insulin-stimulated PI 3K activity from mock transfected cells was approximately 20 % of cells transfected with wildtype p85a and p110a (data not shown).
Establishing the underlying basis for defective insulin action in people with clinical syndromes of extreme insulin resistance remains a challenging problem. Apart from insulin receptor gene mutations, monogenic causes of severe insulin resistance have been elusive. Mutations in IRS-1 are uncommon in severe insulin resistance, although one person with a missense mutation in IRS-1 has been described [47] . The Gly 972 Arg IRS-1 polymorphism has been associated with Type II diabetes [48, 49] as have mutations in the PTB domain of IRS-1 [50] . The evidence implicating the Arg 409 Gln mutation in the p85a subunit of PI 3K as a causative factor in the severe insulin resistance of the family described in this report is, however, arguably the strongest for the existence of an inherited post-receptor defect in human insulin action.
